 GlycoMimetics NASDAQ:GLYC was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued to clients and investors on Friday, Zacks.com reports. The firm currently has a 3.00 price objective on the biotechnology companys stock. According to Zacks, GlycoMimetics, Inc. is a biotechnology company. The company focused on ... 